Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028
Fate Therapeutics Reports Q1 2026 Financial Results and Majo...
Sign in to continue:
Fate Therapeutics Reports Q1 2026 Financial Results and Majo...
Lite Strategy, Inc. Q3 2026 Results: Investor Analysis ...
SmartRent, Inc. 8-K: Detailed Investor Update on 2026 Annual...
Silexion Therapeutics Corp Announces Initiation of GMP Clini...
Eightco Holdings (NASDAQ: ORBS) Announces \$340 Million Trea...
Mettler-Toledo International Inc. Announces 2026 Long-Term I...
Beasley Broadcast Group Q1 2026 Financial Report: Detailed I...
Knight-Swift Transportation Holdings Announces Quarterly Cas...
Assertio Holdings to Be Acquired by Zydus Worldwide DMCC for...
Salt Investments Limited: TT Oil Appointed Distributor for E...